26 articles
Most people who suffer a stroke aren’t treated in time to prevent long-term and often permanent effects on speech, cognition and motor function.
John Orwin, President and CEO of Atreca, a biopharmaceutical company, discusses their drug Discovery Platform and how they are thinking differently abou...
David Vossler, MD, FAAN FACNS FAES, Department of Neurology, University of Washington, discusses the recent U.S. Learn more on Health Professional Radio.
Raymond Douglas, an oculoplastic surgeon, discusses the approval of TEPEZZA™ (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED), the f...
Gustavo Alva, psychiatrist, discusses mood episodes, such as depression, mixed episodes, and mania, why diagnosing bi-polar disorder remains challenging...
Jens Hillengass of Roswell Park Comprehensive Cancer Center, discusses the newly FDA approved immunotherapy combination, Empliciti® (elotuzumab), to tr...
Michael Polydefkis discusses hereditary ATTR amyloidosis and the recently FDA-approved Alnylam's ONPATTRO™, which is the first and only treatment appr...
A significant discovery on how Plasmodium falciparum (the parasite that causes malaria) moves fast to avoid getting caught by the immune cells has been ...
A new treatment for primary axillary hyperhidrosis called Qbrexza (glycopyrronium) has been approved by the US Food And Drug Administration (FDA).
Andrew Blauvelt Presenter: Neal Howard Guest Bio: Andy Blauvelt hails from Portland, OR, and is President and Investigator at Oregon Medical Research Ce...